Evidence map›Paper›PMID 15994801›Full record

ArticleJournal of virology2005

The V1, V2, and V3 regions of the human immunodeficiency virus type 1 envelope differentially affect the viral phenotype in an isolate-dependent manner.

Cheryl J Saunders, Ruth A McCaffrey, Irina Zharkikh, Zane Kraft, Susan E Malenbaum, Brian Burke, Cecilia Cheng-Mayer, Leonidas Stamatatos

Abstract read
In one paragraph

Article in Journal of virology, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 77 papers.

0numbers the graph read from it
0cells of the map it votes in
77citing papers in PubMed
2.9field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

77 citing papers in PubMed, 116 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

17 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 1 country.

Cheryl J SaundersSeattle Biomedical Research Institute, 307 Westlake Avenue North, Seattle, WA 98109, USA.
Ruth A McCaffrey
Irina Zharkikh
Zane Kraft
Susan E Malenbaum
Brian Burke
Cecilia Cheng-Mayer
Leonidas Stamatatos
University of Washington · USAaron Diamond AIDS Research Center · USCenter for Infectious Disease Research · USNorth Seattle College · US

Funding

VACCINE EFFICACY OF MODIFIED HIV ENVELOPESR01AI047708 · NIAID · SEATTLE BIOMEDICAL RESEARCH INSTITUTE · PI STAMATATOS, LEONIDAS · 2000 to 2010
$5.0M
Simian Immunodeficiency VIrus PathogenesisR37AI041945 · NIAID · AARON DIAMOND AIDS RESEARCH CENTER · PI CHENG-MAYER, CECILIA C · 2001 to 2010
$5.0M
Vaccine Efficacy of Modified HIV EnvelopesR56AI047708 · NIAID · SEATTLE BIOMEDICAL RESEARCH INSTITUTE · PI STAMATATOS, LEONIDAS · 2012 to 2012
$540k
PHENOTYPIC AND GENETIC DETERMINANTS OF SHIV PATHOGENESISR01AI041945 · NIAID · AARON DIAMOND AIDS RESEARCH CENTER · PI CHENG-MAYER, CECILIA C · 1997 to 2000
$304k
NIAID NIH HHS AI41945NIAID NIH HHS AI47708NIAID NIH HHS R01 AI041945NIAID NIH HHS R01 AI047708NIAID NIH HHS R37 AI041945NIAID NIH HHS R56 AI047708
6 · The paper itself

Abstract

It is well documented that removal of the V1V2 region or of the V2 loop alone from the envelope glycoprotein of human immunodeficiency virus type 1 (HIV-1) or simian immunodeficiency virus (SIV) increases the susceptibility of these viruses to neutralization by antibodies. The specific role of the V1 loop in defining the neutralization susceptibility of HIV is, however, not well documented. Our current studies indicate that although the V1V2 region is a global modulator of the HIV-1 neutralization susceptibility, the individual roles the V1 and V2 loops have in defining the neutralization susceptibility profile of HIV-1 differ and in some cases are opposite. While deletion of the V2 loop renders the virus more susceptible to neutralization by antibodies that recognize diverse epitopes, in particular certain ones located in the CD4 binding site and the V3 loop, deletion of the V1 loop renders the virus refractory to neutralization, especially by antibodies that recognize CD4-induced epitopes and certain CD4-site binding antibodies. Our current studies also indicate that the relative involvement of the V2 loop of the HIV-1 envelope during virus-cell entry appears to be envelope background dependent. As a result, although deletion of the V2 loop from the clade B, R5-tropic SF162 HIV-1 virus resulted in a virus that was replication competent, the same modification introduced on the background of two other R5-tropic isolates, SF128A (clade B) or SF170 (clade A), abrogated the ability of these envelopes to mediate virus-cell entry.

Indexed as

Amino Acid SequenceAntibodies, MonoclonalBinding SitesCD4 AntigensHIV-1HumansMembrane FusionMolecular Sequence DataPhenotypeViral Envelope ProteinsVirus ReplicationAntibodies, MonoclonalCD4 AntigensViral Envelope Proteins

Identifiers

PMID15994801
PMCPMC1168758
OpenAlexW2125692679

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.